|
Prognostic value of tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer (BC): A focus on inflammatory BC. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Merck |
Research Funding - Roche Italy (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Incyte; Lilly; Novartis |
Research Funding - AstraZeneca (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - bioTheranostics; Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; Gilead Sciences; merck; Novartis; Pfizer |
|
|
Consulting or Advisory Role - AstraZeneca/MedImmune; AstraZeneca/MedImmune; Gilead Sciences |
|
|
Honoraria - Ellipses Pharma |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celcuity; Daichi-Sankyo; Foundation Medicine; GlaxoSmithKline; Guardant Health; Hengrui Therapeutics; Lilly; Menarini; Merck; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen; Veracyte |
Speakers' Bureau - Daiichi Sankyo; Foundation Medicine; Lilly; Menarini; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen |
Research Funding - Merck (Inst) |
Travel, Accommodations, Expenses - Daichii Sankyo; Pfizer; Roche/Genentech |
|
|
Research Funding - Menarini Silicon Biosystems |
|
|
|
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Celcuity; Lilly; Menarini; Olaris; Sermonix Pharmaceuticals; Syantra |
Research Funding - Angle; AstraZeneca; Lilly; Menarini Silicon Biosystems; Merck |